The Federal Register published notice 2026-23141, attributed to FDA and its parent HHS department, on 2026-11-13. Its official title is “Determination That DIBENZYLINE (Phenoxybenzamine Hydrochloride) Oral Capsule, 10 Milligrams, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide.
DailyMed lists Structured Product Labeling version 2 for the reviewed Bremelanotide label family with a published date of 2026-11-09. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for ANDA 216996 with status AP dated 2026-10-29, and names calcitonin salmon among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 214412 with status AP dated 2026-10-23, and names teriparatide among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 7 for the reviewed Insulin glargine-aldy label family with a published date of 2026-10-19. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 40 for the reviewed Linaclotide label family with a published date of 2026-10-19. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for ANDA 211255 with status AP dated 2026-09-24, and names linaclotide among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 217060 with status AP dated 2026-09-21, and names lutetium lu-177 dotatate among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 6 for the reviewed Insulin glargine-aldy label family with a published date of 2026-09-21. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 10 for the reviewed Teriparatide label family with a published date of 2026-09-21. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for ANDA 218217 with status AP dated 2026-09-18, and names lanreotide acetate among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for NDA 218525 with status AP dated 2026-09-14, and names lutetium lu-177 dotatate among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 40 for the reviewed Tirzepatide label family with a published date of 2026-09-02. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for ANDA 220919 with status AP dated 2026-08-31, and names difelikefalin acetate among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for NDA 220605 with status AP dated 2026-08-28, and names rusfertide acetate among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for NDA 213225 with status AP dated 2026-08-26, and names leuprolide acetate among the application record's active ingredients.
The Federal Register published notice 2026-17222, attributed to FDA and its parent HHS department, on 2026-08-24. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide and Octreotide.
The Federal Register published notice 2026-16998, attributed to FDA and its parent HHS department, on 2026-08-20. Its official title is “Advisory Committee; Endocrinologic and Metabolic Drugs Advisory Committee; Renewal,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide.
DailyMed lists Structured Product Labeling version 19 for the reviewed Abaloparatide label family with a published date of 2026-08-17. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 62 for the reviewed Dulaglutide label family with a published date of 2026-08-10. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 9 for the reviewed Tesamorelin label family with a published date of 2026-07-31. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The Federal Register published notice 2026-15285, attributed to FDA and its parent HHS department, on 2026-07-29. Its official title is “Product-Specific Guidances; Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon, Liraglutide, Semaglutide, Teriparatide, Tirzepatide and Vosoritide.
The Federal Register published notice 2026-15149, attributed to FDA and its parent HHS department, on 2026-07-28. Its official title is “Pediatric Advisory Committee (PAC); Notice of Meeting; Establishment of a Public Docket; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Dalbavancin.
FDA convened its Pharmacy Compounding Advisory Committee on July 23-24, 2026, to discuss free-base and acetate bulk drug substances across seven peptide-related groups.
The official Drugs@FDA dataset lists original submission 1 for ANDA 209526 with status AP dated 2026-07-20, and names carfilzomib among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 6 for the reviewed Liraglutide label family with a published date of 2026-07-14. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 2 for the reviewed Glucagon label family with a published date of 2026-07-09. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 5 for the reviewed Insulin glargine-aldy label family with a published date of 2026-07-08. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The Federal Register published notice 2026-13492, attributed to FDA and its parent HHS department, on 2026-07-06. Its official title is “Determination That VASOPRESSIN IN SODIUM CHLORIDE (vasopressin) 0.9%, Injection, 50 units/50 milliliters (1 unit/milliliters) Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Vasopressin.
DailyMed lists Structured Product Labeling version 10 for the reviewed Leuprolide label family with a published date of 2026-07-06. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for ANDA 212972 with status AP dated 2026-07-01, and names liraglutide among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 17 for the reviewed Exenatide label family with a published date of 2026-06-30. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 19 for the reviewed Semaglutide label family with a published date of 2026-06-30. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 9 for the reviewed Teriparatide label family with a published date of 2026-06-30. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The Federal Register published notice 2026-12937, attributed to FDA and its parent HHS department, on 2026-06-26. Its official title is “List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Extension of Comment Period,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide, Semaglutide and Tirzepatide.
The official Drugs@FDA dataset lists original submission 1 for ANDA 213155 with status AP dated 2026-06-15, and names liraglutide among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 2 for the reviewed Insulin glargine-aldy label family with a published date of 2026-06-05. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for ANDA 219604 with status AP dated 2026-06-04, and names dalbavancin hydrochloride among the application record's active ingredients.
The Federal Register published notice 2026-11062, attributed to FDA and its parent HHS department, on 2026-06-03. Its official title is “Elite Laboratories, Inc. et al.; Withdrawal of Approval of 16 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Vasopressin.
DailyMed lists Structured Product Labeling version 1 for the reviewed Insulin glargine-aldy label family with a published date of 2026-06-02. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 39 for the reviewed Linaclotide label family with a published date of 2026-06-01. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The Federal Register published notice 2026-10277, attributed to FDA and its parent HHS department, on 2026-05-22. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Palopegteriparatide.
DailyMed lists Structured Product Labeling version 18 for the reviewed Semaglutide label family with a published date of 2026-05-22. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 11 for the reviewed Afamelanotide label family with a published date of 2026-05-13. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 19 for the reviewed Leuprolide label family with a published date of 2026-05-11. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for ANDA 212068 with status AP dated 2026-05-06, and names vasopressin among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 212069 with status AP dated 2026-05-06, and names vasopressin among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 38 for the reviewed Tirzepatide label family with a published date of 2026-05-06. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The Federal Register published notice 2026-08552, attributed to FDA and its parent HHS department, on 2026-05-01. Its official title is “List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon, Liraglutide, Semaglutide and Tirzepatide.
The Federal Register published notice 2026-08435, attributed to FDA and its parent HHS department, on 2026-04-30. Its official title is “Determination That OZEMPIC (Semaglutide) Solution, 2 Milligrams Per 1.5 Milliliters Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Semaglutide.
FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the list of bulk substances that 503B outsourcing facilities may use for compounding.
The official Drugs@FDA dataset lists original submission 1 for ANDA 218740 with status AP dated 2026-04-29, and names cetrorelix acetate among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for BLA 761412 with status AP dated 2026-04-29, and names insulin glargine-aldy among the application record's active ingredients.
The Federal Register published rule 2026-07863, attributed to FDA and its parent HHS department, on 2026-04-22. Its official title is “Medical Devices; Clinical Chemistry and Clinical Toxicology Devices; Classification of the Setmelanotide Eligibility Gene Variant Detection System,” and PeptideScanner's exact reviewed identity mapping connects the document to Setmelanotide.
The Federal Register published notice 2026-07361, attributed to FDA and its parent HHS department, on 2026-04-16. Its official title is “Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List,” and PeptideScanner's exact reviewed identity mapping connects the document to BPC-157, Emideltide, Epitalon, KPV, MOTS-c, Semax and TB-500.
DailyMed lists Structured Product Labeling version 17 for the reviewed Semaglutide label family with a published date of 2026-04-02. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 14 for the reviewed Setmelanotide label family with a published date of 2026-04-02. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for NDA 220934 with status AP dated 2026-04-01, and names orforglipron calcium among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 212552 with status AP dated 2026-03-30, and names liraglutide among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 60 for the reviewed Dulaglutide label family with a published date of 2026-03-25. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 25 for the reviewed Lixisenatide label family with a published date of 2026-03-20. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for ANDA 215245 with status AP dated 2026-03-11, and names liraglutide among the application record's active ingredients.
The Federal Register published notice 2026-04546, attributed to FDA and its parent HHS department, on 2026-03-09. Its official title is “Aspen Global Inc. c/o Lachman Consultant Services, Inc., et al.; Withdrawal of Approval of 46 New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide.
DailyMed lists Structured Product Labeling version 16 for the reviewed Semaglutide label family with a published date of 2026-03-05. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for ANDA 215864 with status AP dated 2026-03-04, and names calcitonin salmon among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 37 for the reviewed Tirzepatide label family with a published date of 2026-03-03. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for ANDA 219981 with status AP dated 2026-02-27, and names desmopressin acetate among the application record's active ingredients.
The Federal Register published notice 2026-03963, attributed to FDA and its parent HHS department, on 2026-02-27. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Octreotide and Semaglutide.
The official Drugs@FDA dataset lists original submission 1 for ANDA 218602 with status AP dated 2026-02-26, and names dalbavancin hydrochloride among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 3 for the reviewed Liraglutide label family with a published date of 2026-02-26. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 36 for the reviewed Tirzepatide label family with a published date of 2026-02-26. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for NDA 219873 with status AP dated 2026-02-25, and names desmopressin acetate among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 217063 with status AP dated 2026-02-24, and names liraglutide among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 217234 with status AP dated 2026-02-24, and names liraglutide among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 15 for the reviewed Semaglutide label family with a published date of 2026-02-12. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The Federal Register published notice 2026-02786, attributed to FDA and its parent HHS department, on 2026-02-12. Its official title is “Jeremy Spencer Brown: Final Debarment Order,” and PeptideScanner's exact reviewed identity mapping connects the document to Semaglutide.
The official Drugs@FDA dataset lists original submission 1 for ANDA 213382 with status AP dated 2026-02-11, and names glatiramer acetate among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 214022 with status AP dated 2026-02-11, and names glatiramer acetate among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 10 for the reviewed Afamelanotide label family with a published date of 2026-02-06. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 32 for the reviewed Tirzepatide label family with a published date of 2026-02-05. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 2 for the reviewed Octreotide label family with a published date of 2026-02-02. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 31 for the reviewed Tirzepatide label family with a published date of 2026-01-23. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 38 for the reviewed Linaclotide label family with a published date of 2026-01-16. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for ANDA 217590 with status AP dated 2026-01-14, and names liraglutide among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 16 for the reviewed Exenatide label family with a published date of 2026-01-12. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 14 for the reviewed Semaglutide label family with a published date of 2026-01-06. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 8 for the reviewed Tesamorelin label family with a published date of 2026-01-02. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.